Predictors of response to chronic hepatitis C treatment

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Lavanchy D. The global burden of hepatitis C. Liver Int.29(Suppl. 1),74–81 (2009).
  MedlineGoogle Scholar
• 2  Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis.5(9),558–567 (2005).
  MedlineGoogle Scholar
• 3  Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. The National Academic Press Washington, DC, USA (2010).
  Google Scholar
• 4  Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology51(3),729–733 (2010).
  MedlineGoogle Scholar
• 5  Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin. Liver Dis.10(4),919–940 (2006).
  MedlineGoogle Scholar
• 6  Kanwal F, Hoang T, Kramer JR et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology140(4),1182–1188 (2011).
  MedlineGoogle Scholar
• 7  Davis GL, Alter MJ, El-Serag H et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology138(2),513–521 (2010).
  MedlineGoogle Scholar
• 8  Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology54(4),1433–1444 (2011).▪▪ Main guideline for HCV treatment.
  MedlineGoogle Scholar
• 9  Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology130(4),1086–1097 (2006).
  Medline CASGoogle Scholar
• 10  Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitisC genotype 1-infected slow responders. Hepatology46(6),1688–1694 (2007).
  Medline CASGoogle Scholar
• 11  Sanchez-Tapias JM, Diago M, Escartin P et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology131(2),451–460 (2006).
  Medline CASGoogle Scholar
• 12  Buti M, Lurie Y, Zackharova NG et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology52(4),1201–1207 (2010).
  Medline CASGoogle Scholar
• 13  Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol.49(4),634–651 (2008).▪ Good explanation of predictors of response to pegylated interferon/ribavirin.
  Medline CASGoogle Scholar
• 14  Jacobson IM, Brown RS Jr, McCone J et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology46(4),982–990 (2007).
  Medline CASGoogle Scholar
• 15  Huang CF, Yang JF, Dai CY et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J. Infect. Dis.201(5),751–759 (2010).
  Medline CASGoogle Scholar
• 16  Poordad F, McCone J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med.364(13),1195–1206 (2011).
  Medline CASGoogle Scholar
• 17  Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med.364(25),2405–2416 (2011).
  Medline CASGoogle Scholar
• 18  Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med.364(13),1207–1217 (2011).
  Medline CASGoogle Scholar
• 19  Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med.364(25),2417–2428 (2011).
  Medline CASGoogle Scholar
• 20  Poynard T, Colombo M, Bruix J et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology136(5),1618–1628 (2009).
  Medline CASGoogle Scholar
• 21  Pearlman BL, Ehleben C. Retreatment of chronic hepatitis C-genotype 1-infected relapsers to peginterferon/ribavirin with consensus interferon/ribavirin or with extended duration therapy peginterferon/ribavirin. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, USA, 30 October–1 November 2009 (Abstract 815).
  Google Scholar
• 22  Jensen DM, Marcellin P, Freilich B et al. Retreatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann. Intern. Med.150(8),528–540 (2009).
  MedlineGoogle Scholar
• 23  Bacon BR, Shiffman ML, Mendes F et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology49(6),1838–1846 (2009).
  Medline CASGoogle Scholar
• 24  Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology138(2),447–462 (2010).
  Medline CASGoogle Scholar
• 25  Derbala M, Amer A, Bener A et al. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J. Viral. Hepat.12(4),380–385 (2005).
  Medline CASGoogle Scholar
• 26  Lam KD, Trinh HN, Do ST et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment naive chronic hepatitis C genotype 6. Hepatology52(5),1573–1580 (2010).
  Medline CASGoogle Scholar
• 27  Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med.357(2),124–134 (2007).
  Medline CASGoogle Scholar
• 28  Wartelle-Bladou C, Le Folgoc G, Bourliére M, Lecomte L. Hepatitis C therapy in non-genotype 1 patients: the near future. J. Viral. Hepat.19(8),525–536 (2012).
  Medline CASGoogle Scholar
• 29  Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol.55(1),192–206 (2011).
  Medline CASGoogle Scholar
• 30  Jacobson IM, Pawlotsky JM, Afdhal NH et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J. Viral. Hepat.19(Suppl. 2),1–26 (2012).▪▪ Excellent guideline to understanding new HCV treatment.
  MedlineGoogle Scholar
• 31  Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med.140(5),346–355 (2004).
  Medline CASGoogle Scholar
• 32  Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol.49(4),634–651 (2008).
  Medline CASGoogle Scholar
• 33  Thomas DL. Predicting the response to the treatment of hepatitis C virus infection. Clin. Liver Dis.1(2),46–48 (2012).
  Google Scholar
• 34  European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol.55(2),245–264 (2011).
  MedlineGoogle Scholar
• 35  Ridruejo E, Adrover R, Cocozzella D et al. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of peginterferon – ribavirin in daily practice. Ann. Hepatol.9(1),46–51 (2010).
  Medline CASGoogle Scholar
• 36  Kumada H, Toyota J, Okanoue T et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J. Hepatol.56(1),78–84 (2012).
  Medline CASGoogle Scholar
• 37  Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature461(7262),399–401 (2009).
  Medline CASGoogle Scholar
• 38  Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet.41(10),1105–1109 (2009).
  Medline CASGoogle Scholar
• 39  Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature461(7265),798–801 (2009).
  Medline CASGoogle Scholar
• 40  Thompson AJ, Muir AJ, Sulkowski MS et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology139(1),120–129 (2010).
  Medline CASGoogle Scholar
• 41  Ridruejo E, Solano A, Marciano S et al. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 argentine patients treated with peg IFN and ribavirin. Ann. Hepatol.10(4),452–457 (2011).
  Medline CASGoogle Scholar
• 42  Jacobson IM, Catlett I, Marcellin P et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver Berlin, Germany, 30 March–3 April 2011 (Abstract 1369).
  Google Scholar
• 43  Poordad F, Bronowicki JP, Gordon SC et al.IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver Berlin, Germany, 30 March–3 April 2011 (Abstract 12).
  Google Scholar
• 44  Poordad F, Bronowicki JP, Gordon SC et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology143(3),608–618 (2012).
  MedlineGoogle Scholar
• 45  Bronowicki JP, Hezode C, Bengtsson L et al. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. Presented at: 47th Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, 18–22 April 2012 (Abstract 1094).
  Google Scholar
• 46  Pol S, Aerssens J, Zeuzem S et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver Berlin, Germany, 30 March–3 April 2011 (Abstract 13).
  Google Scholar
• 47  Bruno S, Vierling JM, Esteban R et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of SPRINT-2 and RESPOND-2 studies. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver Berlin, Germany, 30 March–3 April 2011 (Abstract 7).
  Google Scholar
• 48  McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology123(4),1061–1069 (2002).
  Medline CASGoogle Scholar
• 49  Mitra D, Davis KL, Beam C et al. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health13(4),479–486 (2010).
  MedlineGoogle Scholar
• 50  Lo Re V 3rd, Teal V, Localio AR et al. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann. Intern. Med.155(6),353–360 (2011).
  MedlineGoogle Scholar
• 51  Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J. Hepatol.43(3),425–433 (2005).
  Medline CASGoogle Scholar
• 52  Mangia A, Thompson AJ, Santoro R et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology54(3),772–780 (2011).
  Medline CASGoogle Scholar
• 53  Reddy KR, Bruno S, Rossaro L et al. Predictors of sustained virologic response among previously untreated patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa-2b/ribavirin (PR). Presented at: 46th Annual Meeting of the European Association for the Study of the Liver Berlin, Germany, 30 March–3 April 2011 (Abstract 466).
  Google Scholar
• 54  Zeuzem S, Vierling JM, Esteban R et al. Predictors of sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus peginterferon alfa-2b/ribavirin. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver Berlin, Germany, 30 March–3 April 2011 (Abstract 291).
  Google Scholar
• 55  Foster GR, Zeuzem S, Andreone P et al. Subanalyses of the telaprevir lead-in arm in the REALIZE study: Response at week 4 is not a substitute for prior null response categorization. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver Berlin, Germany, 30 March–3 April 2011 (Abstract 6).
  Google Scholar
• 56  Telaprevir, package insert. Vertex Pharmaceuticals, MA, USA.
  Google Scholar
• 57  Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med.365(11),1014–1024 (2011).
  Medline CASGoogle Scholar
• 58  Boceprevir, package insert. Merck, NJ, USA.
  Google Scholar
• 59  Jacobson IM, Marcellin P, Zeuzem S et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology56(2),567–575 (2012).
  Medline CASGoogle Scholar
• 60  Bacon B, Bruno S, Schiff E et al. Predictors of sustained virologic response among poor interferon responders when boceprevir is added to peginterferon alfa-2b/ribavirin. Presented at: Annual Meeting of the American Association for the Study of Liver Diseases San Francisco, California, 4–8 November 2011 (Abstract 33).
  Google Scholar
• 101  Efficacy of a 12-week regimen of telaprevir, peginterferon, and ribavirin in subjects with interleukin-28B (IL28B) CC genotype in treatment-naive and prior relapser subjects (CONCISE). http://clinicaltrials.gov/ct2/show/NCT01459913
  Google Scholar
• 102  Clinical Care Options. Hepatitis. http://clinicaloptions.com/hepatitis
  Google Scholar